Educational Interviews

Educational interviews are at the centre of the PCR experience. Whether it’s an expert opinion on a new technique and tool or any of the key topics that interest you, you can find it here. Available online during and after every course, we spotlight the latest procedures, devices, tools and techniques on TAVI, stents and scaffolds, below the knee, LAA closure, STEMI, chronic heart failure, mitral valve replacement and repair and other topics.

Filter By

131 results

Highlights from ACC 2017

How important was interventional cardiology at this year’s American College of Cardiology Scientific sessions? Join D. Capodanno as he reviews the breaking sessions and others to reveal what aspects of our specialty were touched on during this recent international meeting and why. From structural and coronary to imaging, as well as important developments in pharmacology see which issues had the greatest impact: Was it iFR or FFR?  TAVI? New agents? Cost effectiveness?  Get your “take-home” message here…

This interview was recorded at the American College of Cardiology Scientific Sessions 2017 (ACC 17).

Carotid stenting, present and future

What is the role of carotid artery stenting? Can it be considered today as a first choice in the treatment of critical bifurcation carotid stenosis? M. Roffi and A. Cremonesi explore the different dimensions of this procedure, its history, devices, operator experience, as well as existing limitations and challenges. What technological innovations hold promise and what do we expect from the future? Join us …

Optimal antithrombotic strategies after ACS: GEMINI-ACS-1 - ACC.17

What does the future hold for optimal antithrombotic strategies after ACS? G. Steg leads us through one of the key, late-breaking trials at ACC.17, calling it a “stepping stone” to an exciting future in antiplatelet therapy. Learn why as we examine current DAPT and search for an alternative that can be both effective and cause less bleeding. Can the family of low dose anticoagulation agents such as rivaroxaban be the answer? Hear about the “bottom line” out here…

This interview was recorded at the American College of Cardiology Scientific Sessions 2017 (ACC.17).

IFR-SWEDEHEART and DEFINE-FLAIR: iFR vs. FFR

Join W. Wijns as he explores issues surrounding the adoption of iFR or FFR as highlighted by two trials presented at ACC2017 – IFR-SWEDEHEART, from the well-known Swedish registry and DEFINE-FLAIR. Can the design of these trials shed light on the efficacy of either of these physiologic measurements? What important, and previously missing data, was finally reported? And the results of these trials – what impact will they have on the way you practice? Join us and find out…

This interview was recorded at the American College of Cardiology Scientific Sessions 2017 (ACC.17).

RESOLVE and SAVORY: subclinical leaflet thrombosis in transcatheter and surgical bioprosthetic aortic valves

Better understanding of reduced leaflet motion in bioprosthetic aortic valves due to subclinical leaflet thrombosis is critical, and R. Makkar discusses two, single hospital registries which look at this phenomenon. Is there a difference between surgical and transcatheter aortic valves? Can DAPT strategies or the use of non-vitamin K antagonist anticoagulants (NOACs) play a role here? What is the effect of this phenomenon on clinical outcomes? Death rates? Strokes? Transient ischaemic attacks? Can these findings impact future guidelines concerning aortic valve replacement? Learn more…

This interview was recorded at the American College of Cardiology Scientific Sessions 2017 (ACC 17).

Lessons from the ABSORB everolimus-eluting bioresorbable vascular scaffold programme

P. Serruys offers an overview and evaluation of the past, ongoing and upcoming clinical trials regarding the Absorb everolimus-eluting bioresorbable vascular scaffold (BRS). Were the concerns generated by earlier trials justified? What impact has this had on the current ABSORB III trial, and has this trial provided us with the results we expected after 1 or 2 years from this device? What will new iterations of this device have to offer? Understand the essential BVS message from a recognised expert …

This interview was recorded at the American College of Cardiology Scientific Sessions 2017 (ACC.17).

ABSORB III Trial: Two-year outcomes

Absorb everolimus-eluting bioresorbable vascular scaffold (BRS) vs. XIENCE stent? We join S. Ellis, the study’s lead author, as we examine our evolving understanding of BRS in this non-inferiority trial. What were the principal endpoints and results? What was the cause of an observed “increase in risk”? Did this impact the study results? What lessons have we learned? Vessel size? Technique? Join us as we examine a device which is still challenging, but increasingly understood…

This interview was recorded at the American College of Cardiology Scientific Sessions 2017 (ACC.17).

FOURIER: Use of PCSK9 inhibitor evolocumab - ACC.17

This study – presented during an ACC.17 late breaking trial session and simultaneously published in NEJM – tracked the use of the PCSK9 inhibitor evolocumab. What were the clinical profiles of the over 27,000 high-risk patients enrolled in this multi-year trial? Were they on statins? What were the results on risk reduction in primary and secondary endpoints and why does this constitute a “beautiful regression”? Join M. Sabatine, the study’s lead author, and find the answers to these and other questions here…

This interview was recorded at the American College of Cardiology Scientific Sessions 2017 (ACC.17).

Lessons from the SURTAVI trial - ACC.17

International in scope, demonstrating non-inferiority as a goal, this trial uses an early iteration of the CoreValve and the new Evolut-R bioprosthesis. Join M. Gilard as she captures the key message of SURTAVI, the second trial to compare TAVI to surgery in intermediate risk patients. Learn what was the observed rate of mortality, stroke, paravalvular leak or pacemaker use and understand why this can have an impact on future guidelines for patients eligible for TAVI. Learn more today…

This interview was recorded at the American College of Cardiology Scientific Sessions 2017 (ACC 17).

SURTAVI: TAVI versus surgery in intermdiate risk AS patients

Your patient has symptomatic, severe aortic stenosis and an intermediate level of operative risk – how would you treat them? Surgery? What if TAVI was shown to be as safe and effective as the surgical approach, even in these lower risk patients? Join M. J. Reardon as he explains the results of a trial that can impact our future use of TAVI. Learn how levels of risk were defined and how the results further support the aspirations of this technique and the newer generation of devices used here…

This interview was recorded at the American College of Cardiology Scientific Sessions 2017 (ACC.17).